Middle East & Africa Pharmaceutical Drug Delivery Market

The report "Middle East & Africa Pharmaceutical Drug Delivery Market by Route of Administration (Injectable [Syringe, Auto injector], Oral [Tablet, Capsule, Syrup], Topical, Nasal, Ocular, Rectal), Application (Cancer, Diabetes, CVD, Ophthalmic) - Forecast to 2031" is projected to reach USD 48.22 billion by 2031 from USD 38.20 billion in 2026, at a CAGR of 4.8%.

Browse 250 market data Tables and 100 Figures spread through 220 Pages and in-depth TOC on "Middle East & Africa Pharmaceutical Drug Delivery Market, By Route of Administration (Injectable [Syringe, Auto injector], Oral [Tablet, Capsule, Syrup], Topical, Nasal, Ocular, Rectal), Application (Cancer, Diabetes, CVD, Ophthalmic) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/middle-east-africa-pharmaceutical-drug-delivery-market-73937239.html

The Middle East & Africa pharmaceutical drug delivery market is expanding due to rising cases of chronic diseases, particularly in major regional nations such as Saudi Arabia, the UAE, and South Africa. Besides, the market is observing the rollout of more biologics and complex therapies as specialty care demand increases and healthcare investments expand in the Gulf and African regions. Therefore, local healthcare systems, both public and private, are turning to drug delivery solutions that enhance patient adherence while remaining precise, safe, and convenient.

Drug delivery devices such as autoinjectors, inhalers, wearable injectors, lipid nanoparticles, and controlled-release formulations have grown in popularity in the Middle East & Africa. Such a trend is evidence of a general shift toward advanced therapeutic modalities, including mRNA-based drugs, cell and gene therapies, and high-viscosity biologics. In addition to maintaining drug stability, such delivery systems can help deliver the right dosage and improve patient adherence, which is very important in MEA, given the increasing demand for home-based care, self-administration, and chronic disease management programs throughout the region.

Nevertheless, the market still has to overcome the challenges of extremely expensive research and development and the technical complexities associated with drug delivery device combinations. Specialized manufacturing requirements, stringent regulatory standards, and long product development periods remain critical issues. On top of that, health authorities in the Middle East & Africa, namely the SFDA, MOHAP, and SAHPRA, are gradually elevating their health, safety, and compatibility standards to levels that are much more difficult to attain. The manufacturers in the region will thus have to work harder and incur higher costs due to these new regulations.

Based on route of administration, injectable drug delivery segment to record highest CAGR during forecast period.

Injectable drug delivery is expected to be the fastest-growing segment of the Middle East & Africa market, by value. The main reason is the rise in prevalence of chronic diseases such as diabetes, cancer, autoimmune disorders, and cardiovascular conditions, not only in Saudi Arabia and the UAE but also in South Africa, Egypt, Nigeria, and Kenya. Moreover, the increasing use of biologics, biosimilars, monoclonal antibodies, and advanced immunotherapies has led to greater dependence on injection as the mode of drug administration. These drugs are highly dependent on parenteral delivery due to their low oral bioavailability, molecular instability, and the need for precise systemic delivery.

Further support for this segment's growth comes from breakthroughs in both formulation science and drug-delivery device engineering. Innovations such as autoinjectors, prefilled syringes, connected injectors, needle-safety systems, depot injectables, and wearable on-body injectors are increasingly being adopted across MEA. These new technologies not only help deliver the right dose and reduce contamination risk, but also make the treatment more comfortable, drastically reduce the frequency of doctor visits, and thus align with the increased trend toward home-based care and self-administration in the region. Consequently, injectable drug delivery technologies have been increasingly incorporated into healthcare services across both the public and private sectors in the Middle East & Africa.

Cancer segment to register the second-highest CAGR in Middle East & Africa pharmaceutical drug delivery market during forecast period.

The pharmaceutical drug delivery market in the Middle East & Africa for cancer segment is expanding rapidly. Factors that have largely contributed to the trend include a significant rise in cancer incidence across countries such as Saudi Arabia, the UAE, Egypt, Morocco, South Africa, and Nigeria, along with the increasing introduction of targeted therapies, immunotherapies, and personalized medicines in the region. Oncology treatment in MEA is heavily dependent on sophisticated drug-delivery mechanisms, such as biologics, monoclonal antibodies, antibody-drug conjugates, and cytotoxic chemotherapeutic agents, all of which most often require injectable or infusion-based delivery routes. Cancer treatment effectiveness largely depends on delivery, and, in the case of drug therapy, controlled, accurate, and well-regulated delivery ensures patients receive maximum therapeutic benefit with minimal toxicity. MEA health systems are gradually expanding cancer care capacity through specialized centers and comprehensive oncology programs; the need for precise drug delivery is rising accordingly.

In the Middle East and Africa, the pharmaceutical industry has been investing heavily in the development of drug-delivery devices for some time. This trend has led to the increased popularity of injectable, implantable, and localized drug delivery systems. Emerging technologies in oncology treatment include long-acting depot formulations, nanoparticle-based delivery systems, on-body injector devices, and liposomal encapsulation methods. These innovations are either in development or commercially available and aim to enhance therapeutic efficacy and patient adherence. This growing trend underscores the significant role that novel drug delivery technologies play in oncology treatments across the entire Middle East and African region.

Based on facility of use, hospital segment is largest contributor of Middle East & Africa pharmaceutical drug delivery market.

The hospital segment, with the largest share of the Middle East & Africa pharmaceutical drug delivery market, is primarily driven by the high prevalence of chronic and acute diseases in the region, which require complex treatments that are mostly administered in controlled clinical environments. Hospitals are the main points of oncology, infectious disease management, critical care, and biologics, not only in the Gulf countries but also in South Africa, Egypt, and Kenya. The availability of trained medical professionals, advanced diagnostic and monitoring facilities, and the ability to handle high-viscosity biologics, monoclonal antibodies, radiopharmaceuticals, and other specialty therapies have all led to this trend.

Hospital settings are even more important as the use of long-acting injectables, controlled-release formulations, and implantable delivery systems increases, all of which require professional supervision for accurate dosing and safety. Besides, centralized procurement systems, government-backed reimbursement schemes, and a steady flow of investments in hospital upgrades across the Middle East & Africa are among the factors that keep this segment dominant.

Key Market Players

Some prominent players in the Middle East & Africa pharmaceutical drug delivery market include Sanofi (France), Pfizer Inc. (US), Novartis AG (Switzerland), AstraZeneca (UK), GSK plc (UK), Hikma Pharmaceuticals plc (UK), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novo Nordisk A/S (Denmark), BD (US), B. Braun (Germany), Abbott (US), Amgen (US), Johnson & Johnson (US), Viatris Inc. (US), Aspen Holdings (South Africa), EVA Pharma (Egypt), Cipla (India), West Pharmaceutical Services Inc. (US), and Julphar (UAE).

Don’t miss out on business opportunities in Middle East & Africa pharmaceutical drug delivery market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com